Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Hydroperoxide SCHEMBL27806184 | 0.88 | LMNA (0.35) | LMNATSHRHCAR2ALDH1A1ALOX15 | |
| SCHEMBL7250555 | 0.88 | FAAH (0.36) | LMNATSHRHCAR2ALDH1A1ESR1 | |
| SCHEMBL13133071 | 0.87 | TSHR (0.46) | LMNATSHRHCAR2ALDH1A1CA12 | |
| SCHEMBL452059 | 0.86 | ALDH1A1 (0.52) | LMNATSHRHCAR2ALDH1A1ESR1 | |
| SCHEMBL15986332 | 0.85 | HCAR2 (0.39) | LMNATSHRHCAR2ALDH1A1ESR1 | |
| SCHEMBL10087932 | 0.85 | LMNA (0.52) | LMNATSHRHCAR2ALDH1A1CA12 | |
| SCHEMBL8861415 | 0.84 | HSD17B10 (0.38) | LMNATSHRHCAR2ALDH1A1ESR1 | |
| SCHEMBL7870958 | 0.84 | HCAR2 (0.38) | LMNATSHRHCAR2ALDH1A1ESR1 | |
| SCHEMBL7250554 | 0.84 | TSHR (0.33) | LMNATSHRHCAR2 | |
| SCHEMBL14715673 | 0.83 | TSHR (0.42) | LMNATSHRHCAR2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418723-B1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEM CORP (JP) | 2018-09-19 | — | — | EP | claimed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | claimed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-20080161394-A1 | Cosmetic composition comprising at least one volatile carbonic acid ester | L'OREAL S.A. (FR) | 2008-07-03 | — | — | US | claimed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | claimed |
| CN-115458808-B | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-20260112701-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY INCLUDING NONAQUEOUS ELECTROLYTIC SOLUTION | MU IONIC SOLUTIONS CORPORATION (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4708437-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY INCLUDING NONAQUEOUS ELECTROLYTIC SOLUTION | MU Ionic Solutions Corporation (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-12494506-B2 | Nonaqueous electrolytic solution and energy device including the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-12-09 | — | — | US | disclosed |
| US-12469878-B2 | Nonaqueous electrolyte solution and energy device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-11-11 | — | — | US | disclosed |
| US-12456760-B2 | Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-10-28 | — | — | US | disclosed |
| EP-3926652-B1 | NON-AQUEOUS ELECTROLYTE FOR POWER STORAGE ELEMENT, NON-AQUEOUS ELECTROLYTE POWER STORAGE ELEMENT, AND METHOD FOR PRODUCING NON-AQUEOUS ELECTROLYTE POWER STORAGE ELEMENT | GS YUASA INT LTD (JP) | 2025-09-24 | — | — | EP | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-5338878-A | Solvent extraction using hydrocarbons selective for extracting alkyl carboantes, and second solvent of water to extract alkanol | AMOCO CORPORATION (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260112701-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY INCLUDING NONAQUEOUS ELECTROLYTIC SOLUTION | NHERF1, SLC9A2, SCNN1B | LMNA 3498/4885TSHR 3995/4885HCAR2 4836/4885 |
| US-12469878-B2 | Nonaqueous electrolyte solution and energy device | HCN2, SLC9A1, VDAC1 | LMNA 4238/4885TSHR 3528/4885HCAR2 3605/4885 |
| US-12456760-B2 | Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery | NHERF1, NAP1L1, NAF1 | LMNA 4235/4885TSHR 3537/4885HCAR2 3284/4885 |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | LMNA 3425/4885TSHR 3809/4885HCAR2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.